Endo International 

$0
68
+$0+0% Wednesday 20:16

統計

當日最高
-
當日最低
-
52週高點
-
52週低點
-
成交量
-
平均成交量
-
市值
0
本益比
-
股息殖利率
-
股息
-

財報

7Aug預期
Q4 2021
Q1 2022
Q2 2022
Q3 2022
Q4 2022
Q1 2023
Q2 2023
-0.14
0.19
0.51
0.84
預期EPS
0.022
實際EPS
不適用

財務

-121.79%利潤率
未盈利
2018
2019
2020
2021
2022
2023
2.01B營收
-2.45B淨利

其他人也在關注

此清單是根據在 Stock Events 上追蹤 ENDPQ 的使用者自選建立的。這不是投資建議。

競爭對手

此清單為基於近期市場事件的分析。並非投資建議。

關於

Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States and internationally. Its Branded Pharmaceuticals segment provides branded prescription products, including XIAFLEX to treat adult patients with Dupuytren's contracture; SUPPRELIN LA to treat central precocious puberty in children; NASCOBAL nasal spray to treat vitamin B12 deficiency; AVEED to treat hypogonadism; QWO, an injectable treatment for moderate to severe cellulite in the buttocks of adult women; PERCOCET to treat moderate-to-moderately-severe pain; TESTOPEL an implantable pellet indicated for TRT in conditions associated with a deficiency or absence of endogenous testosterone; EDEX to treat erectile dysfunction; LIDODERM a topical patch product containing lidocaine for the relief of pain; and products for the pain management and urology. The company's Sterile Injectables segment manufactures VASOSTRICT, a vasopressin injection; ADRENALIN, a non-selective adrenergic agonist; and APLISOL, which is a sterile aqueous solution, as well as generic sterile injectable products, including ertapenem for injections and ephedrine sulfate injections. Its Generic Pharmaceuticals segment offers solid oral extended-release, solid oral immediate-release, liquids, semi-solids, patches, powders, ophthalmic products, and sprays. The company's International Pharmaceuticals segment offers specialty pharmaceutical products in various therapeutic areas comprising attention deficit hyperactivity disorder, pain, women's health, oncology, and transplantation. The company sells its branded pharmaceuticals and generics to specialty physicians, retailers, clinics, government agencies, doctors, retail and specialty pharmacies, and specialty distributors. Endo International plc was founded in 1920 and is headquartered in Dublin, Ireland. On August 16, 2022, Endo International plc, along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York.
Show more...
執行長
Blaise Coleman
員工
2931
國家
IE
ISIN
IE00BJ3V9050
WKN
000A1XE6M

上市

0 Comments

分享你的想法

FAQ

Endo International 今天的股價是多少?
ENDPQ 目前價格為 $0 USD,過去 24 小時上漲了 +0%。在圖表上更密切關注 Endo International 股價表現。
Endo International 的股票代號是什麼?
根據交易所不同,股票代號可能會有所差異。例如,在 交易所,Endo International 的股票以代號 ENDPQ 進行交易。
Endo International 去年的營收是多少?
Endo International 去年的營收為 2.01BUSD。
Endo International 去年的淨利是多少?
ENDPQ 去年的淨收益為 -2.45BUSD。
Endo International 有多少名員工?
截至 April 01, 2026,公司共有 2,931 名員工。
Endo International 位於哪個產業?
Endo International從事於Professional, Scientific, and Technical Services產業。
Endo International 何時完成拆股?
Endo International 最近沒有進行任何拆股。
Endo International 的總部在哪裡?
Endo International 的總部位於 IE 的 Dublin。